Covalent BTK inhibitors, such as zanubrutinib, acarbrutinib, and ibrutinib, have demonstrated favorable efficacy during treatment of CLL by inhibiting BTK. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.